Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Differential Effects of HIV Protease Inhibitors on Release and Activation of Platelet-Derived TGF-β1: Potential Association with HIV-Linked CVD

Kouzbari Karim, DDS, Gostynska Sandra, MS, Sonia Elhadad, PhD, Dube Pratibha, MS, Jeffrey Laurence, MD, Jasimuddin Ahamed, PhD

Blood (2019) 134 (Supplement_1): 2341.

https://doi.org/10.1182/blood-2019-126225

Published: 2019

Journal Articles

Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial — SAKK 39/10

Felicitas - Hitz, MD, Thomas - Pabst, MD, Dagmar - Hess, MD, Marianne Kraus, Lenka Besse, Urban Novak, MD, Katja - Seipel, MD, Stephanie - Rondeau, Silvia - Stüdeli, Simona Berardi, MD, Samaras Panagiotis, MD, Ulrich Mey, MD, Christoph Driessen, MD

Blood (2017) 130 (Supplement 1): 1884.

https://doi.org/10.1182/blood.V130.Suppl_1.1884.1884

Published: 2017

Journal Articles

Incidence and Risk Factors for Venous Thrombosis in Human Immunodeficiency Virus (HIV) Infection, Data from the Dutch Athena Cohort Study

James Francis Borjas-Howard, MD MSc, Casper Rokx, MD PhD, Colette Smit, PhD, Ferdinand Wit, MD PhD, Elise Pieterman, MD MSc, Karina Meijer, MD PhD, Bart Rijnders, MD PhD, Wouter Bierman, MD PhD, Vladimir Tichelaar, MD PhD

Blood (2016) 128 (22): 271.

https://doi.org/10.1182/blood.V128.22.271.271

Published: 2016

Journal Articles

The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

Christoph Driessen, MD PhD, Rouven Müller, MD, Urban Novak, MD, Nathan Cantoni, MD, Daniel Betticher, Nicolas Mach, Michael Gregor, Panagiotis Samaras, MD, Catherine Berset, Stephanie Rondeau, Hanne Hawle, MD, Felicitas Hitz, MD, Thomas Pabst, MD PhD, Thilo Zander, MD

Blood (2016) 128 (22): 487.

https://doi.org/10.1182/blood.V128.22.487.487

Published: 2016

Journal Articles

SAKK 65/08: A Phase I Dose Escalation Study of Bortezomib in Combination with Nelfinavir in Patients with Advanced Hematologic Malignancies

Christoph Driessen, MD, Jürgen Bader, Marianne Kraus, PhD, Markus Jörger, MD PhD, Hilde Rosing, PhD, Gregoire Berthod, MD, Felicitas Hitz, MD, Catherine Berset, PhD, Alexandros Xyrafas, Hanne Hawle, MD, Hermann S Overkleeft, PhD, Christiana Sessa, MD, Alwin Huitema, PhD, Ulrich JM Mey, Thomas Pabst, MD, Roger von Moos, MD, Dagmar Hess, MD

Blood (2014) 124 (21): 4747.

https://doi.org/10.1182/blood.V124.21.4747.4747

Published: 2014

Journal Articles

Targeting Glycolysis and Compensatory Mitochondrial Metabolism In An In Vivo Xenograft Model Of Multiple Myeloma With FDA Approved Ritonavir and Metformin

Sevim Dalva-Aydemir, MS, Kehinde U.A. Adekola, MBBS, Jennifer Koblinski, PhD, Noopur Raje, MD, Steven T. Rosen, MD, FRCPA, Mala Shanmugam, PhD

Blood (2013) 122 (21): 1922.

https://doi.org/10.1182/blood.V122.21.1922.1922

Published: 2013

Journal Articles

Identification of Endoplasmic Reticulum Stress Inducing Agents by Antagonizing Autophagy: A New Potential Strategy for Identification of Anti-Cancer Therapeutics in B-Cell Malignancies.

Emilia Mahoney, MD, PhD, Sara L Cole, PhD, Kami Maddocks, MD, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Xiaoli Zhang, PhD, MS, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2012) 120 (21): 2473.

https://doi.org/10.1182/blood.V120.21.2473.2473

Published: 2012

Journal Articles

SAKK 65/08: A Phase I Trial of the HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib Identifies Nelfinavir As FDA Approved, Oral Drug that Inhibits the Proteasome and Induces Proteotoxic Stress in Vivo and has Potential Antimyeloma Activity.

Christoph Driessen, MD, Dagmar Hess, MD, Thomas Pabst, MD, Sarah R Haile, Markus Joerger, MD, Roger von Moos, MD, Catherine Berset, Susanne Crowe, Hilde Rosing, PhD, Hermen S Overkleeft, Christiana Sessa, Marianne Kraus

Blood (2012) 120 (21): 2956.

https://doi.org/10.1182/blood.V120.21.2956.2956

Published: 2012

Journal Articles

Targeting Glycolysis and Compensatory Mitochondrial Metabolism in Multiple Myeloma with FDA Approved Ritonavir and Metformin Via Synthetic Lethality

Kehinde U. A. Adekola, M.B.B.S, Maylyn Martinez, Steven T. Rosen, MD, FRCPA, Mala Shanmugam, PhD

Blood (2012) 120 (21): 4016.

https://doi.org/10.1182/blood.V120.21.4016.4016

Published: 2012

Journal Articles

Nelfinavir Activates Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus Lytic Cycle by Inducing ER Stress

Courtney Shirley, BS, Nene Kalu, MS, Richard F Ambinder, MD, PhD

Blood (2011) 118 (21): 5011.

https://doi.org/10.1182/blood.V118.21.5011.5011

Published: 2011

Journal Articles

Myeloma Exhibits Dependence on Atypical Glucose Transporters: Targeting MCL-1 Through GLUT4 Inhibition

Mala Shanmugam, PhD, Javelin C Cheng, MS, Samuel K McBrayer, Steven T. Rosen, MD, FRCPA

Blood (2011) 118 (21): 1850.

https://doi.org/10.1182/blood.V118.21.1850.1850

Published: 2011

Journal Articles

The HIV Protease Inhibitor Nelfinavir: A Unique Oral Drug That Inhibits the Proteasome and AKT-Phosphorylation, Induces ER Stress and Sensitizes Bortezomib-Refractory Primary Myeloma Cells and Primary AML Cells towards Bortezomib

Christoph Driessen, MD, Jürgen Bader, Marianne Kraus

Blood (2010) 116 (21): 4069.

https://doi.org/10.1182/blood.V116.21.4069.4069

Published: 2010

Journal Articles

Inhibition of Autophagy Promotes Bortezomib-Mediated Cell Death in Myeloma Cells

Terry H. Landowski, PhD, Aluvia M Escalante, Andrew Jefferson, Robert T Dorr, Ronald Lynch

Blood (2008) 112 (11): 3677.

https://doi.org/10.1182/blood.V112.11.3677.3677

Published: 2008

Journal Articles

Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir

M. Zahidunnabi Dewan, Jun-nosuke Uchihara, Kazuo Terashima, Mitsuo Honda, Tetsutaro Sata, Mamoru Ito, Nobutaka Fujii, Kimiharu Uozumi, Kunihiro Tsukasaki, Masao Tomonaga, Yoko Kubuki, Akihiko Okayama, Masakazu Toi, Naoki Mori, Naoki Yamamoto

Blood (2006) 107 (2): 716–724.

https://doi.org/10.1182/blood-2005-02-0735

Published: 2006

Journal Articles

Acquired Bortezomib (Velcade®)-Resistance Is Accompanied by Downmodulation of Proteasome Activity and Upregulation of Tripeptidyl Peptidase II (TPPII) and a Ubiquitin-Specific Protease.

Christoph Driessen, Jeanette Gogel, Marianne Kraus, Huib Ovaa, Alexander Beck, Thomas Rückrich

Blood (2005) 106 (11): 3375.

https://doi.org/10.1182/blood.V106.11.3375.3375

Published: 2005

Journal Articles

Saquinavir Inhibits Proliferation and Promotes Apoptosis in Imatinib-Resistant Chronic Myelogenous Leukemia Lines and Inhibits CFU-GM Growth in CML Blastic Crisis.

Fabio S. Timeus, MD, PhD, Nicoletta Crescenzio, BSc, Alessandra Doria, BSc, Luiselda C. Foglia, BSc, Daniele Bertin, MD, Giuseppe Saglio, MD, Pier Angelo Tovo, MD

Blood (2005) 106 (11): 4846.

https://doi.org/10.1182/blood.V106.11.4846.4846

Published: 2005

Journal Articles

Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss

Barbara N. Phenix, Julian J. Lum, Zelin Nie, Jaime Sanchez-Dardon, Andrew D. Badley

Blood (2001) 98 (4): 1078–1085.

https://doi.org/10.1182/blood.V98.4.1078

Published: 2001

Journal Articles

The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals

Surendra Chavan, Sangeetha Kodoth, Rajendra Pahwa, Savita Pahwa

Blood (2001) 98 (2): 383–389.

https://doi.org/10.1182/blood.V98.2.383

Published: 2001

Journal Articles

HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression–independent mechanism

Wei Lu, Jean-Marie Andrieu

Blood (2000) 96 (1): 250–258.

https://doi.org/10.1182/blood.V96.1.250

Published: 2000

NARROW

Differential Effects of HIV Protease Inhibitors on Release and Activation of Platelet-Derived TGF-β1: Potential Association with HIV-Linked CVD

Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial — SAKK 39/10

Incidence and Risk Factors for Venous Thrombosis in Human Immunodeficiency Virus (HIV) Infection, Data from the Dutch Athena Cohort Study

The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

SAKK 65/08: A Phase I Dose Escalation Study of Bortezomib in Combination with Nelfinavir in Patients with Advanced Hematologic Malignancies

Targeting Glycolysis and Compensatory Mitochondrial Metabolism In An In Vivo Xenograft Model Of Multiple Myeloma With FDA Approved Ritonavir and Metformin

Identification of Endoplasmic Reticulum Stress Inducing Agents by Antagonizing Autophagy: A New Potential Strategy for Identification of Anti-Cancer Therapeutics in B-Cell Malignancies.

SAKK 65/08: A Phase I Trial of the HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib Identifies Nelfinavir As FDA Approved, Oral Drug that Inhibits the Proteasome and Induces Proteotoxic Stress in Vivo and has Potential Antimyeloma Activity.

Targeting Glycolysis and Compensatory Mitochondrial Metabolism in Multiple Myeloma with FDA Approved Ritonavir and Metformin Via Synthetic Lethality

Nelfinavir Activates Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus Lytic Cycle by Inducing ER Stress

Myeloma Exhibits Dependence on Atypical Glucose Transporters: Targeting MCL-1 Through GLUT4 Inhibition

The HIV Protease Inhibitor Nelfinavir: A Unique Oral Drug That Inhibits the Proteasome and AKT-Phosphorylation, Induces ER Stress and Sensitizes Bortezomib-Refractory Primary Myeloma Cells and Primary AML Cells towards Bortezomib

Inhibition of Autophagy Promotes Bortezomib-Mediated Cell Death in Myeloma Cells

Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir

Acquired Bortezomib (Velcade®)-Resistance Is Accompanied by Downmodulation of Proteasome Activity and Upregulation of Tripeptidyl Peptidase II (TPPII) and a Ubiquitin-Specific Protease.

Saquinavir Inhibits Proliferation and Promotes Apoptosis in Imatinib-Resistant Chronic Myelogenous Leukemia Lines and Inhibits CFU-GM Growth in CML Blastic Crisis.

Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss

The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals

HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression–independent mechanism

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only